Introduction
============

Gastric cancer is in the top three causes of cancer mortality worldwide ([@ref-28]) and in 2012 was the fifth most common cancer with more than 70% occurring in developing countries and with especially high incidences in Eastern Asia. Rates in men are generally twice those in women ([@ref-9]). Although advances in treatment can help prolong patient life, mortality rates are still high in many countries because established cancer screening programs are limited and presentation is very often at the late stage ([@ref-12]). While there exist several novel screening techniques available for early detection, such as testing for pepsinogens and *H. pylori* factors in the circulation ([@ref-32]; [@ref-31]; [@ref-29]; [@ref-34]), these strategies may not be appropriate in a relatively low risk country like Thailand.

In general, blood samples can be particularly useful in cancer screening by, for example, a proteomics approach ([@ref-26]; [@ref-27]). Both circulating tumor cells and cell free DNA may have prognostic value ([@ref-17]; [@ref-30]). Although challenges exist, effective methodology has been established ([@ref-5]; [@ref-36]), and the search is on for serum cancer markers with good sensitivity and specificity ([@ref-16]; [@ref-23]; [@ref-37]). There are several reports that DNA methylation can be applied with tumor tissues harvested after surgical operation or biopsy for prediction of prognosis. Moreover, its presence in serum offers clear advantages for non-invasive detection. DNA methylation plays an important role in silencing tumor suppressor genes during cancer development by adding a methyl group from S-adenosyl-L-methionine to the cytosine or adenine ring in CpG islands of genes ([@ref-25]; [@ref-43]). DNA methylation can thus suppress the transcription of many tumor suppressor genes protecting against cancer initiation and progression ([@ref-19]), and thus offer tools for screening.

The *PCDH10* gene is classified as a tumor suppressor gene in the protocadherin family, a cadherin subfamily. *PCDH10* function specifies cell--cell adhesion via Ca^2+^ in tissue morphogenetic processes ([@ref-1]; [@ref-33]) and apoptosis by upregulation of *Fas*, *Caspase 8*, *Jun*, *CDKN1A*, and *HTATIP2* ([@ref-46]). The methylation of *PCDH10* is involved in metastasis and has been found in many carcinomas, including colorectal, nasopharyngeal, esophageal, hepatocellular, breast, cervical, and lung cancers, and also in gastric cancer ([@ref-26]; [@ref-27]; [@ref-7]). The RAS association domain family 1A gene (*RASSF1A*) or *RASSF1A* blocks cell-cycle progression and inhibits cyclin D1 accumulation. Furthermore, RAS regulates a pro-apoptotic pathway by binding to the RAS effectors, NORE1 and *RASSF1A*, and activates apoptotic protein kinases such as MST1 ([@ref-6]). *RASSF1A* is also classified as a tumor suppressor gene, and its methylation may lead to increased cell proliferation, invasion, and metastasis ([@ref-14]).

There have been reports about alteration of either *PCDH10* or *RASSF1A* in gastric cancer tissues or cell lines ([@ref-3]; [@ref-6]; [@ref-39]), but none of the studies investigated both genes together. In addition, to our knowledge, only a few specifically addressed the methylation of *RASSF1A* in DNA extracted from peripheral blood ([@ref-2]; [@ref-41]). Thus, the aim of this research was to assess the methylation status of *PCDH10* and *RASSF1A* of DNA in blood samples of gastric cancer patients. This study also included an investigation of clinicopathological characteristics affecting the survival rate of this patient group in northeastern Thailand.

Materials and Methods
=====================

Population and specimens
------------------------

Specimens were obtained from gastric cancer patients who visited two of the largest hospitals in the northeast of Thailand (Srinagarind Hospital at Khon Kaen University---a medical school hospital, and Khon Kaen Hospital---a regional public hospital) and had resided in the area for at least five years. The patients were initially diagnosed by the specialist and confirmed by histopathology and diagnosed according to the International Classification of Diseases for Oncology in the period between October 2002 and 2006. All patients were followed-up until death or the end of the study period (31 October, 2012). This study was approved by the Khon Kaen University Ethics Committee for Human Research (HE 581260, dated 20 July, 2015). General demographic characteristics, such as age and sex, were assessed along with clinicopathological parameters of gastric cancer.

EDTA blood samples were collected by venipuncture from 101 patients diagnosed with gastric cancer according to the International Classification of Diseases for Oncology (ICD-O 3rd) and confirmed by histopathology. Each case was matched with two controls (a total of 202) by gender, age (±3 years), hospital, and provincial residence. The participants with gastrointestinal disease were excluded. All participants provided written informed consent prior to the beginning of the study. The participants who refused, or unable to answer our interview were excluded from the study.

Plasma was separated by centrifugation at 2000 × g for 15 min at room temperature. All samples were stored at −20 °C until DNA extraction. All patients were followed-up until death or the end of the study period (31 October, 2012). Data of interest were retrieved from medical records including age on the day of diagnosis, gender, site of cancer, histopathology, histological grading, stage of disease, and tumor metastasis. The classical endpoint was survival time. The clinicopathological status of each patient was checked from medical records and by linkage with the death registry of the Thai national statistics database.

DNA extraction
--------------

The cell-free DNA was extracted from plasma using the standard protocol of the Genomic DNA Mini Kit (Geneaid Biotech). Briefly, 200 µl of plasma was mixed with 200 µl of working solution and incubated at 60 °C for 10 min. The DNA isolation was then processed as described in the manufacturer's protocol. DNA samples were stored at −80 °C until used.

Gene methylation by methylation-specific polymerase chain reaction
------------------------------------------------------------------

Methylation-specific PCR (MSP) was used to evaluate methylation status based on bisulfite reactivity. Firstly, DNA was denatured to create single-stranded DNA and then modified with sodium bisulfite followed by a PCR using two pairs of primers: (1) specific for methylated DNA and (2) specific for unmethylated DNA. Bisulfite modification was used to perform the conversion of unmethylated cytosine to uracil except for the 5-methylcytosines. Bisulfite conversion was carried out up to 2 µg of extracted DNA in accordance with the instructions of EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). PCR reactions were carried out in a total volume of 25 µl per 1 reaction containing 2.5 µl of 10X PCR buffer, 0.5 µl of 50 mM Mgcl~2~, 1 µl of 10 mM dNTP, 0.5 µl of forward primer (10 µM), 0.5 µl of reverse primer (10 µM), and 1 µl of template modified DNA.

To investigate the methylation of *PCDH10* promoters, the orders of bases in unmethylation and methylation of *PCDH10* forward and reverse primers were as follows: 5′-GTTGTT AAATAGATATGTTATGT-3′ and 5′-CTAAAAACTAAAAACTTTCCACA-3′; 5′-TCGTTA AATAGATACGTTACGC-3′, and 5′-TAAAAACTAAAAACT TTCCGCG-3′, respectively. MSP conditions were setup as follows: a hot start at 95 °C for 15 min followed by 55 cycles of 95 °C for 30 s, 59 °C for 30 s, 72 °C for 30 s, and finally 72 °C for 8 min (final extension).

The sequences of specific primers in unmethylation of *RASSF1A* promoters (forward and reverse primers) were as follows: 5′ GGTTTTGTGAGAGTGTGTTTAG-3′ and 5′-CACTAACAAACACAAACCAAAC-3′; and 5′-GGGTTTTGCGAGAGCGCG-3′, and 5′-GCTAACAAAGCGGAACCG-3′ for *RASSF1A* methylation, respectively. The condition of MSP was setup as follows: a hot start at 95 °C for 15 min followed by 55 cycles of 95 °C, for 30 s, 59 °C for 30 s, 72 °C for 30 s, and finally 72 °C for 8 min (final extension). Positive methylated DNA was human peripheral blood leukocyte DNA which was treated with 75 units of M.SssI methylase, and positive unmethylated was non-treated DNA.

The amplified 150 bp products from the methylated and unmethylated *PCDH10* and *RASSF1A*were run on 2% agarose gel with 1,000 bp DNA ladder, and stained with ethidium bromide and visualized in UV light.

Statistical analysis
--------------------

Statistical comparisons of prevalence data were performed using the Fisher's exact test. Where indicated, *p* \< 0.001 is denoted \*\*\*; 0.001 \< *p* \< 0.01 is denoted \*\*, and 0.01 \< *p* \< 0.05 is denoted \*. Survival times were calculated for each patient and started from the date of diagnosis until the date of the death or the end of following-up period (31 October, 2012). Percentages were used to describe categorical data. Means with standard deviations or medians with ranges were used to describe continuous data characteristics. The survival probabilities were determined by the Kaplan--Meier method. Comparisons were made with the log-rank test. Univariate and multivariate Cox proportional hazard regression models were used to estimate the association between explanatory variables and survival experience, and the results presented in the form of crude and adjusted hazard ratios (HR) and their 95% confidence intervals (CI). All analyses were conducted using Stata version 10.0 (<http://www.stata.com/>). *P*-values are two-tailed and reported without any formal correction for multiple comparisons.
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###### Influence of clinicopathological factor, *RASSF1A* and *PCDH10* methylation on survival of 101 gastric cancer patients.

![](peerj-04-2112-g008)

  Variable                                           Number (%)   Median survival (months)   Crude HR (95%CI)                                        *p*-value   Adjusted HR 95%CI                                       *p*-value
  -------------------------------------------------- ------------ -------------------------- ------------------------------------------------------- ----------- ------------------------------------------------------- -----------
  Gender                                                                                                                                                                                                                 
  Female                                             44(43.6)     7.8(5.7−12.3)              1                                                                                                                           
  Male                                               57(56.4)     10.2(6.1−14.3)             0.81(0.53−1.23)                                         0.33        --                                                      --
  Age (years)                                                                                                                                                                                                            
  ≤40                                                17(16.8)     8.8(1.9−19.8)              1                                                                                                                           
  41--50                                             25(24.7)     8.5(4.6−12.4)              0.61(0.14−2.63)                                                                                                             
  51--60                                             29(28.7)     8.3(6.7−20.8)              0.43(0.10−1.84)                                                                                                             
  ≥61                                                30(29.7)     7.5(5.4−18.8)              0.44(0.10−1.90)                                         0.30        --                                                      --
  Region of cancer                                                                                                                                                                                                       
  Upper site (cardia and fundus)                     18(17.8)     12.8(4.3−20.2)             1                                                                                                                           
  Body                                               7(6.9)       11.4(5.1−21.3)             0.88(0.34−2.23)                                                                                                             
  Lower site (antrum and pyrolus)                    48(47.5)     8.6(5.7−14.3)              1.00(0.57−1.77)                                         0.65        --                                                      --
  Histopathology                                                                                                                                                                                                         
  Adenocarcinoma (NOS)                               70(69.3)     8.7(5.7−12.8)              1                                                                                                                           
  Adenocarcinoma (intestinal and diffuse type)       31(30.7)     8.6(6.0−16.5)              0.93(0.59−1.45)                                         0.76        --                                                      --
  Histology grading (Goseki classification)                                                                                                                                                                              
  Group I, II (well or moderate differentiation)     21(20.8)     8.8(4.8−21.3)              1                                                                                                                           
  Group III, IV (poor differentiation)               59(58.4)     8.7(6.7−13.0)              1.08(0.64−1.82)                                         0.65        --                                                      --
  Stage grouping (TNM classification)                                                                                                                                                                                    
  Mild and moderate stage (IA, IB, II, IIIA, IIIB)   23(22.8)     17.3(6.8−39.1)             1                                                                                                                           
  Severe stage (IV)                                  54(53.4)     8.6(5.7−11.5)              2.56(1.45−4.52)[^\*\*\*^](#table-1fn1){ref-type="fn"}   0.001       2.62(1.74-3.97)[^\*\*\*^](#table-1fn1){ref-type="fn"}   0.001
  Metastasis                                                                                                                                                                                                             
  No                                                 33(32.7)     11.5(6.7−16.5)             1                                                                                                                           
  Yes                                                68(67.3)     7.3(4.5−8.8)               1.76(1.13−2.74)[^\*\*^](#table-1fn2){ref-type="fn"}     0.01        1.09(0.69−1.71)                                         0.77
  *RASSF1A* methylation                                                                                                                                                                                                  
  Unmethylation                                      17(16.8)     20.2(5.9−22.6)             1                                                                                                                           
  Methylation                                        84(83.2)     7.8(5.8−10.2)              2.96(1.52−5.76)[^\*\*\*^](#table-1fn1){ref-type="fn"}   0.001       2.33(1.14-4.85)[^\*\*^](#table-1fn2){ref-type="fn"}     0.002
  *PCDH10* methylation                                                                                                                                                                                                   
  Unmethylation                                      6(5.9)       NA                         1                                                                                                                           
  Methylation                                        95(94.1)     8.4(6.1−11.4)              7.23e+s15(NA)                                           NS          --                                                      --

**Notes.**

*p* \< 0.001.

0.001 \< *p* \< 0.01.

Note that for some groupings, it is possible that the information cannot be used as indicated: the region of cancer not known in 28 patients, and this also applies for histology grading (21 patients), and stage grouping (24 patients).

Results
=======

General characteristics of the gastric cancer patients (101), such as gender and age, and frequencies of clinicopathological variables are summarized in [Table 1](#table-1){ref-type="table"}. Findings for the methylation status are shown in [Fig. 1](#fig-1){ref-type="fig"}. With both *PCDH10* and *RASSF1A*, methylation was very rare in controls (2.97% and 5.45%, respectively), but exceedingly common in cancer cases (94.06% in *PCDH10* and 83.17% in *RASSF1A*) with highly significant differences (*p* \< 0.001) using the chi-square test ([Fig. 2](#fig-2){ref-type="fig"}). In the cases group, a total of 83 demonstrated methylation of both genes with only one having *RASSF1A* alone as compared to 12 for *PCDH10* alone ([Fig. 3](#fig-3){ref-type="fig"}).

![The gel electrophoresis of MS-PCR products for methylated (M), unmethelated (U), positive methylated (+M), normal saline (DW), and positive unmethylated (+U) in gastric cancer patients and controls; *PDCH10* (A) and *RASSF1A* (B).](peerj-04-2112-g001){#fig-1}

![Assessment of methylation status of *PCDH10* and *RASSF1A* genes in gastric cancer patients and controls by MSP where indicated, *p* \< 0.001 is denoted \*\*\*; 0.001 \< *p* \< 0.01 is denoted \*\*, and 0.01 \< *p* \< 0.05 is denoted \*.](peerj-04-2112-g002){#fig-2}

![Association of *PCDH10* and *RASSF1A* gene methylations in gastric cancer patients; (−, −) is both unmethylated; (−, +) is the only methylated *RASSF1A*; (+, 1) is the only methylated *PCDH10*; and (+, +) is both methylated where indicated, *p* \< 0.001 is denoted \*\*\*; 0.001 \< *p* \< 0.01 is denoted \*\*, and 0.01 \< *p* \< 0.05 is denoted \*.](peerj-04-2112-g003){#fig-3}

Survival rates for gastric cancer cases
---------------------------------------

The cumulative survival probabilities at 1, 3, 6, and 9 months were 96.0%, 86.9%, 63.6%, and 46.5%. respectively, and the 1, 2, 3, 4, and 5 year survival probabilities were 40.4%, 23.2%, 15.2% 10.1%, and 10.1%, respectively. The median survival time of stomach cancer after diagnosis was 8.07 months (95% CI \[6.0--10.2\]). [Figures 4](#fig-4){ref-type="fig"}--[](#fig-5){ref-type="fig"}[](#fig-6){ref-type="fig"}[7](#fig-7){ref-type="fig"} shows the Kaplan--Meier curves for factors assessed for association with survival: stage, presence of metastasis, and *PCDH10* and *RASSF1A* methylation.

With histology staging by the TNM classification, stage IV had significantly reduced median survival time (8.6 months, *p* \< 0.05) when compared with the lower stages (IA, IB, II, IIIA, IIIB). Similarly, with patients who had a metastasis, a low median survival time was noted (7.3 months, *p* \< 0.01). With *RASSF1A* methylation, there was a large reduction of median survival time (7.8 months as compared with 20.2 months in the unmethylation group, *p* \< 0.001). The median survival time with positive *PCDH10* methylation was just 8.4 months. With the *PCDH10* non-methylation patients no mortality was encountered.

![Survival curve of gastric cancer by stage of cancer status (*n* = 101).](peerj-04-2112-g004){#fig-4}

[Table 1](#table-1){ref-type="table"} also shows the hazard ratios. In the multivariate analysis based on stepwise Cox proportional hazards regression, only *RASSF1A* methylation and stage proved to be significant independent risk factors for survival. However, no analysis of the *PCDH10* methylation data was conducted because of the very low number in the unmethylation group (*n* = 6) compared with the methylation group (*n* = 95). The outcome for this gene therefore remains inconclusive. There were no associations between gastric cancer survival and gender, age, anatomical region of cancer, histopathology, histology grading, or metastasis.

Association of *RASSF1A* and *PCDH10* methylation status in cell-free DNA with clinicopathological parameters of gastric cancer patients
----------------------------------------------------------------------------------------------------------------------------------------

[Table 2](#table-2){ref-type="table"} summarizes the association of *RASSF1A* and *PCDH10* methylation status with various clinicopathological parameters. The aberrant methylation status in both genes was significantly associated with histology grading (differentiation of tumor), TNM stage (stage IV) and lymph node metastasis (*p* \< 0.05). Gender, age, region of cancer, and histopathology were not significantly associated (*p* \> 0.05) with either the *RASSF1A* or the *PCDH10* promoter methylations.

![Survival curve of gastric cancer by *RASSF1A* methylation status (*n* = 101).](peerj-04-2112-g005){#fig-5}

![Survival curve of gastric cancer by *PCDH10* methylation status (*n* = 101).](peerj-04-2112-g006){#fig-6}

![Survival curve of gastric cancer by metastasis status (*n* = 101).](peerj-04-2112-g007){#fig-7}
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###### Clinical characteristics of 101 gastric cancer patients with and without *RASSF1A* and *PCDH10* methylation in plasma DNA.
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  Clinical variables                          *RASSF1A*     *p*-value     *PCDH10*                                      *p*-value                  
  ------------------------------------------- ------------- ------------- --------------------------------------------- ------------- ------------ ---------------------------------------------
  Gender                                                                  0.99                                                                     0.69
  Female                                      37 (44.05%)   7 (41.18%)                                                  42 (44.21%)   2 (33.33%)   
  Male                                        47 (55.95%)   10 (58.82%)                                                 53 (55.79%)   4 (66.67%)   
  Age (years)                                                             1.00                                                                     0.69
  \<50                                        35 (41.67%)   7 (41.18%)                                                  39 (68.42%)   3 (50.00%)   
  \>50                                        49 (58.33%)   10 (58.82%)                                                 56 (31.58%)   3 (50.00%)   
  Region of cancer                                                        0.34                                                                     1.00
  Upper site and Body                         19 (22.62%)   6 (35.29%)                                                  24 (25.26%)   1 (16.67%)   
  Lower site                                  41 (48.81%)   7 (41.18%)                                                  45 (47.37%)   3 (50.00%)   
  Not specific                                24 (28.57%)   4 (23.53%)                                                  26 (27.37%)   2 (33.33%)   
  Histopathology (Adenocarcinoma)                                         1.00                                                                     1.00
  NOS                                         58 (69.05%)   12 (70.59%)                                                 66 (69.47%)   4 (66.67%)   
  Intestinal and diffuse type                 26 (30.95%)   5 (29.41%)                                                  29 (30.53%)   2 (33.33%)   
  Histology grading (Goseki classification)                               0.001[^\*\*\*^](#table-2fn1){ref-type="fn"}                              0.017[^\*\*^](#table-2fn2){ref-type="fn"}
  Not specific                                14 (16.67%)   7 (41.18%)                                                  17 (17.89%)   4 (66.67%)   
  Group I--IV                                 70 (83.33%)   10 (58.82%)                                                 78 (82.11%)   2 (33.33%)   
  Stage grouping (TNM classification)                                     0.002[^\*\*^](#table-2fn2){ref-type="fn"}                                0.023[^\*\*^](#table-2fn2){ref-type="fn"}
  Not specific                                13 (15.48%)   10 (64.71%)                                                 20 (21.05%)   3 (50.00%)   
  I--III                                      17 (20.24%)   6 (29.41%)                                                  20 (22.11%)   3 (50.00%)   
  IV                                          54 (64.29%)   1 (5.88%)                                                   55 (56.84%)   0 (0%)       
  Metastasis                                                              0.005[^\*\*\*^](#table-2fn1){ref-type="fn"}                              0.002[^\*\*\*^](#table-2fn1){ref-type="fn"}
  No                                          27 (39.29%)   12 (11.76%)                                                 33 (34.74%)   6 (100.0%)   
  Yes                                         57 (60.71%)   5 (88.24%)                                                  62 (65.26%)   0 (0%)       

**Notes.**

*p* \< 0.001.

0.001 \< *p* \< 0.01.

Discussion
==========

Although there are many studies related to epigenetic alterations associated with gastric cancer, the accuracy of molecular mechanisms between gastric cancer carcinogenesis and progression remains unclear. A specific prognostic biomarker in tumor tissues is required to predict disease progression in clinicopathological terms ([@ref-10]).

Cell-free DNA from cancer cells, one of non-invasive biomarkers in gastric cancer diagnosis and prognosis, is released to serum ([@ref-8]). Many studies have also observed that the methylation level of *PCDH10* and *RASSF1A* is closely related to gastric cancer tissues, but there are only a few reports of these methylation levels in cell-free DNA. In the present study, the rates for DNA methylation in controls were very low (below 6%). This was in clear contrast to the 94 and 83% found for gastric cancer cases for *PCDH10* and *RASSF1A*, respectively.

This finding is consistent with earlier studies using tumor tissue ([@ref-33]; [@ref-18]; [@ref-40]; [@ref-46]; [@ref-47]) and provides the first such demonstration in Thailand. Furthermore, the high levels of *PCDH10* and *RASSFIA* methylations in plasma samples from cases suggest an ideal new biomarker for gastric cancer. The methylation process is accessible, repeatable, and noninvasive. This study used MSP to evaluate methylation status based on bisulfite reactivity, and bisulfite treated DNA was confirmed. MSP provides a sensitive, quick, and cost-effective test for the methylation status of CpG dinucleotides in a CpG island, making the technique applicable for high throughput analysis of clinical samples ([@ref-13]; [@ref-38]; [@ref-42]).

[@ref-47] reported that *PCDH10* methylation was detected in 82% (85 of 104) of gastric tumors whereas it was found in only 37% (38 of 104) of paired non-tumor tissues (*p* \< 0.001); while the study of [@ref-26]; [@ref-27] showed an even a higher rate of hypermethylation at 86% of gastric cancer tissues and gastric cancer cell lines of *PCDH10*. Regarding *RASSF1A*, the reports provided by [@ref-20] stated that 26% to 66.1% of *RASSF1A* methylation rates occurred in gastric cancer cell lines or tissues ([@ref-39]; [@ref-35]; [@ref-45]). [@ref-39] assessed the association of *RASSF1A* promoter methylation with gastric cancer risk in a comprehensive meta-analysis and documented a significant linkage (*OR* = 12.67; 95% CI \[8.12--19.78\]; *p* \< 0.001).

However, with *PCDH10*, none of the studies about cell-free DNA methylation levels have been measured in blood samples, but in *RASSFIA* methylation was found in 50 (68.5%) of the serum samples of 73 gastric cancers ([@ref-2]) and, in another study,16 (34%) of 47 gastric cancers ([@ref-41]). Consistent with [@ref-24], disease staging is an important factor affecting the survival of gastric cancer patients, especially in terms of the advanced stages of the disease ([@ref-4]; [@ref-24]; [@ref-21]). Our finding that the median survival time of more than 50% of the recruited patients at the severe stage of the disease was about 8 months after diagnosis is consistent with this. Likewise, the patients with metastasis, *RASSF1A* and *PCDH10* methylations also died during the first year. Notably in our finding, the methylation of *RASSF1A* and *PCDH10* was found higher in late-stage patients and were correlated with metastasis and histology.

Our research is the first report about an investigation into DNA methylation and clinicopathological characteristics associated with the survival of gastric cancer patients in a Thai population. Our analyses showed that aberrant *PCDH10* and *RASSF1A* promoter methylation in plasma DNA was associated with shorter overall survival. The occurrence of *PCDH10* and *RASSF1A* methylations in plasma DNA provides additional information with clinical relevance. For our study we recruited patients mainly from rural areas who attended two large regional hospitals. For most of them we found that a presence of gastric cancer was at the severe stage. Methylation detection is useful in drawing attention to extent of development of the cancer such as tumor differentiation, stage, and distant metastasis. This suggests that it may be useful in the clinical application of screening and diagnosis of gastric cancer.

Regarding *RASSF1A* methylation and survival of gastric cancer patients, different studies have reported a link with poor prognosis ([@ref-6]; [@ref-11]). As expected, we found that tumor characteristics, such as stage of cancer and metastasis, were inversely linked to survival, although in the case of metastasis this was confirmed in our multivariate analysis. In line with other studies, stage of disease emerged as an important factor affecting survival of gastric cancer patients ([@ref-44]; [@ref-24]; [@ref-21]; [@ref-4]; [@ref-22]; [@ref-15]).

Conclusions
===========

Gastric cancer is associated with methylated *PCDH10* and *RASSF1A*. In addition, only *RASSF1A* methylation and stage IV were found to be major factors having a direct effect on the survival of Thai gastric cancer patients. Whether the two genes can potentially be used as candidate clinical biomarkers still requires further validation in large scale prospective studies.
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